← Back to Clinical Trials
Recruiting NCT05300971

NCT05300971 Passive Heat Therapy for Lowering Systolic Blood Pressure and Improving Vascular Function in Mid-life and Older Adults

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05300971
Status Recruiting
Phase
Sponsor University of Colorado, Boulder
Condition Aging
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2022-08-01
Primary Completion 2027-11-01

Trial Parameters

Condition Aging
Sponsor University of Colorado, Boulder
Study Type INTERVENTIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 40 Years
Max Age N/A
Start Date 2022-08-01
Completion 2027-11-01
Interventions
Heat therapyThermoneutral water immersion

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study aims to determine the effects of \~12 weeks of repeated hot water immersion ("heat therapy") vs. thermoneutral water immersion on blood pressure and vascular function in late middle-life to older (≥40 years) adults. The study also aims to determine the effects of \~12 weeks of heat therapy on fluid cognitive and cerebrovascular function.

Eligibility Criteria

Inclusion Criteria: * Able to provide informed consent (no clinical diagnosis of dementia or related diseases AND mini mental state exam score \>20). * Willing to accept random assignment to intervention. * Aged 40+ years. * Premenopausal women must not be pregnant (confirmed by urine pregnancy test). * Casual systolic blood pressure 115-159 mmHg. * Sufficiently healthy to undergo heat stress, as determined by the CTRC physician Dr. Wolfe and physician of record Dr. Chonchol based on medical history, physical exam, blood chemistries, and 12-lead ECG at rest and during the graded exercise test. Subjects with established clinical diseases may participate so long it is not determined that heat therapy could be detrimental to their health (determined case-by-case, but examples of subjects who may be excluded include those currently undergoing chemotherapy treatment or chronic kidney disease patients requiring dialysis). * Ability to refrain from the use of dietary supplements, anti-inflamm

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology